Rocket Lab (RKLB) reported revenue of $234.1M in the second quarter ended June 30, 2026, up 62.0% from a year earlier, while still losing money and burning cash. Recent headlines say the company delayed its Neutron rocket again, and in our analysis that matters because Neutron is central to the case for the stock's $30.74B market value. The stock traded at $51.36 on its latest quote on Oct. 19, 2026, up 1.02%, and well below its 52-week high of $151.
Key facts
- Revenue, Q2 FY2026 (quarter ended June 30, 2026): $234.1M, versus analyst expectations of $231.6M and $144.5M in the year-ago quarter.
- Loss per share, same quarter: $0.08, a wider loss than the $0.05832 analysts expected, but narrower than the $0.13 loss a year earlier.
- Cash, as of June 30, 2026: $2.30B in cash and short-term investments against total debt of $133.7M.
- Free cash flow, Q2 FY2026: negative $110.1M (cash from operations minus capital spending).
- Next earnings date: Nov. 9, 2026. Analysts expect revenue of $257.2M and a loss of $0.06742 per share.
- Stock Expert AI MoonshotScore: 27.8, rated Weak.
What happened
The theme: the race for reusable rockets. Launching satellites used to be expensive because rockets were thrown away after one flight. Reusable rockets cut that cost, and the company that can fly often and cheaply wins the most customers. As general industry background, SpaceX dominates today. Headlines this week, including a Benzinga piece, quote Elon Musk saying rivals still cannot catch Starship. Rocket Lab is one of the best-known challengers. As general background, its small Electron rocket already flies regularly. Its bigger, planned rocket, Neutron, is meant to compete for heavier and more lucrative missions.
The latest development. Motley Fool headlines on Oct. 19, 2026 say Rocket Lab pushed back Neutron's debut again. We are not citing a new date or other details here because they are not in the data we used. What the numbers show is a company that is growing quickly while the product that is supposed to justify its valuation keeps slipping.
The quarter itself. Rocket Lab reported revenue of $234.1M for the quarter ended June 30, 2026, beating the analyst average by about $2.4M. The loss per share of $0.08 was wider than the $0.05832 analysts expected. Net income was a loss of $49.3M, narrower than the $66.4M loss a year earlier.
The company splits revenue into product and service lines. In the first quarter ended March 31, 2026, product revenue was $127.5M and service revenue was $72.9M. We do not have the same split for the June quarter in our data, so we cannot say which line drove the latest jump.
The five-quarter trend. Here is how the business has moved since mid-2025:
| Quarter ended | Revenue | Gross margin | Operating margin | Free cash flow | |---|---|---|---|---| | June 30, 2025 | $144.5M | 32.1% | -41.3% | -$55.3M | | Sept. 30, 2025 | $155.1M | 37.0% | -38.0% | -$69.4M | | Dec. 31, 2025 | $179.7M | 38.0% | -28.4% | -$114.2M | | March 31, 2026 | $200.3M | 38.2% | -27.9% | -$77.4M | | June 30, 2026 | $234.1M | 36.1% | -24.6% | -$110.1M |
Three things stand out. First, revenue has risen every quarter. Second, the operating margin (the share of sales left after running costs, before interest and taxes) has improved from -41.3% to -24.6%, meaning losses are shrinking relative to sales. Third, gross margin, which measures profit on each sale before overhead, slipped in the latest quarter to 36.1% from 38.2%, the first decline in the five quarters shown. Cash burn also remains heavy: operating cash flow was negative $84.1M in the June quarter, worse than negative $50.3M in the March quarter.
Why it matters for investors
Growth is real, profit is not here yet. Revenue growth of 62.0% is fast by any standard. But the company lost money on a trailing 12-month basis, with a net margin of -21.5%. Free cash flow has been negative in each of the last five quarters, and the company paid no dividends and bought back no shares.
The balance sheet buys time. Cash and short-term investments of $2.30B far exceed total debt of $133.7M, and FMP reports net debt of negative $2.00B, meaning the company holds more cash than debt. Shareholders' equity was $3.49B. Quarterly free cash outflows of the size shown above are being funded from that pile, so delays that push out revenue from new products are costly but not an immediate threat to solvency. The Altman Z-score, a bankruptcy-risk gauge where higher is safer, is 26.87. The Piotroski score, a nine-point check of financial health, is only 3.
Valuation is demanding. The stock trades at about 39.96 times trailing sales (price/sales). That means investors pay roughly $40 for each $1 of yearly revenue. A P/E ratio is not meaningful when earnings are negative, and it reads -185.48 here. FMP's discounted cash flow model, which estimates what future cash flows are worth today, returns a negative value of -$45.51 per share. That is a mechanical result of current losses, not a forecast, but it shows that today's price rests on cash flows far in the future.
Peers. Rocket Lab is much larger than the other space names in our comparison set:
| Company | Market cap | P/E | Net margin | |---|---|---|---| | Rocket Lab (RKLB) | $30.74B | -185.48 | -21.5% | | Planet Labs (PL) | $4.63B | -12.35 | -95.1% | | Firefly Aerospace (FLY) | $2.79B | -6.96 | -126.6% | | Redwire (RDW) | $2.11B | -5.79 | -57.3% | | Virgin Galactic (SPCE) | $300.8M | -0.69 | -23867.4% |
Rocket Lab's net margin is the least negative of the group, and its market cap is several times larger than any peer's.
What analysts think. Of 21 analyst ratings, 16 are Buy, 4 are Hold and 1 is Sell, for a consensus of "Buy." Analysts' price targets average $105.17, with a median of $108.50, a high of $132.00 and a low of $80.00. Even the lowest target is well above the Oct. 19 price of $51.36. These are analysts' views, not ours, and targets often lag bad news. Several firms reiterated their ratings in the past two weeks, including Citizens on Oct. 16, 2026 and TD Cowen, KeyBanc and Cantor Fitzgerald on Oct. 15, 2026.
Our MoonshotScore. Stock Expert AI's MoonshotScore is 27.8, which we rate Weak. Its pillars are scored relative to the sector: growth 57 (the strongest), safety 42, momentum 26, quality 23 and valuation 21. In plain terms, the score agrees with the story above: growth is a relative strength, while profitability quality, price momentum and valuation are weak.
What could go wrong.
- More Neutron delays. Repeated slips push out revenue from heavier launches and raise the risk that rivals widen their lead.
- Cash burn. Free cash flow worsened in the June quarter. If spending keeps outpacing sales, the company may eventually need to raise money, which can dilute existing shareholders.
- Margins. Gross margin fell in the latest quarter after several quarters of gains.
- Valuation. A high price relative to sales leaves little room for disappointment. The stock's 52-week range of $37.57 to $151 shows how sharply sentiment has swung.
- Insider selling. Among the 30 most recent insider filings, those dated in the last 90 days show 24 sales and no open-market purchases. Insider sales can have many causes, such as pre-planned selling or tax needs, so this is a data point rather than a verdict.
What to watch next
- Nov. 9, 2026 earnings. Analysts expect revenue of $257.2M and a loss of $0.06742 per share for the third quarter. Last time the company beat on revenue but missed on earnings per share.
- Neutron timing. Look for management to give a clear new schedule and explain what caused the slip, and whether it changes spending plans.
- Gross margin. Does it recover from 36.1%, or keep drifting down?
- Free cash flow. Does the quarterly outflow, which was $110.1M in the June quarter, narrow or grow?
- Long-range estimates. Analysts' forecasts for the quarters ending March 30 and June 30, 2029 put revenue at $542.8M and $560.6M, with roughly breakeven EPS, based on just two analysts. That gives a rough sense of the long road the market is pricing in.
Frequently asked questions
Q: Why is Rocket Lab stock down so far from its 52-week high?
The stock traded at $51.36 on its latest quote on Oct. 19, 2026, compared with a 52-week range of $37.57 to $151. The cause of the decline is not established in our data. Headlines on Oct. 19 report a new Neutron delay, but they do not tie it to the fall from the high, and the stock rose 1.02% that day. The stock's valuation does leave it sensitive to disappointment about the company's timeline and cash burn.
Q: Is Rocket Lab profitable?
No. In the quarter ended June 30, 2026, the company reported a net loss of $49.3M, or $0.08 per share, and an operating margin of -24.6%. The loss is smaller relative to sales than a year earlier, when the operating margin was -41.3%, but the company has not yet reached profit.
Q: Does Rocket Lab have enough cash to survive Neutron delays?
As of June 30, 2026, it held $2.30B in cash and short-term investments against $133.7M of debt. Free cash flow was negative $110.1M in the June quarter, so the cushion is being used, but the balance sheet is strong relative to current losses. Longer delays or higher spending could change that, so the Nov. 9, 2026 report is the next checkpoint.
This is educational content, not investment advice. Past performance does not guarantee future results.